InvestorsHub Logo
Followers 82
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

Re: speramus post# 56013

Thursday, 03/10/2016 10:02:50 AM

Thursday, March 10, 2016 10:02:50 AM

Post# of 463238
No additional improvement in the plus arm is a surprise to me -

- no additional improvement in the plus arm so the patent is a non issue


I've had some concern that the rapidly diminishing benefit of donepezil alone would affect the Plus benefit by 6 months into the trial.

This concern may have just been vaporized!

Do you have any thoughts on this?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News